Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model

A nonlinear model predictive control (NMPC) algorithm was developed to dose the chemotherapeutic agent tamoxifen based on a novel saturating-rate, cell-cycle model (SCM). Using daily tumor measurements, the algorithm decreased tumor volume along a specified reference trajectory in simulated animals over 4 months. In mismatch case studies, controllers based on the Gompertz model (GM) yielded equivalent total drug delivered and elapsed time to t(99%) reference step convergence to those obtained using the SCM, though this performance was dependent on the cell-cycle phase of drug effect. Overall, the NMPC algorithm is suitable for dosing chemotherapeutics with regular administration schedules and may be adapted for regularly administered chemotherapeutics other than tamoxifen.

[1]  Earl G. Adams,et al.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[2]  E A Martin,et al.  Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. , 1997, Carcinogenesis.

[3]  Z. Bajzer,et al.  Conceptual frameworks for mathematical modeling of tumor growth dynamics , 1996 .

[4]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  S G Grant,et al.  A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. , 2001, Mathematical biosciences.

[6]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[7]  Evanghelos Zafiriou,et al.  Robust process control , 1987 .

[8]  Urszula Ledzewicz,et al.  Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .

[9]  Julie L. Eiseman,et al.  A Nonlinear Model Predictive Control Algorithm for Breast Cancer Treatment , 2004 .

[10]  Thomas Scheper,et al.  Flow cytometry in biotechnology , 2001, Applied Microbiology and Biotechnology.

[11]  H. Akaike.  A Bayesian extension of the minimum AIC procedure of autoregressive model fitting , 1979 .

[12]  S. Robinson,et al.  Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[13]  R. B. Martin,et al.  Optimal control drug scheduling of cancer chemotherapy , 1992, Autom..

[14]  Kok Lay Teo,et al.  Optimal Control of Drug Administration in Cancer Chemotherapy , 1993 .

[15]  S. Namkoong,et al.  Multiparametric flow cytometric analysis in a breast cancer cell line (MCF‐7) , 2002, The journal of obstetrics and gynaecology research.

[16]  Julie L. Eiseman,et al.  Antitumor activity, distribution, and metabolism of 13-cis -retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice , 1999, Cancer Chemotherapy and Pharmacology.

[17]  John A. Adam,et al.  A mathematical model of cycle-specific chemotherapy , 1995 .